Clinical trials often suffer from inefficient designs and suboptimal resource allocation, leading to increased costs and lower success rates. Traditional trial designs may not adapt to accumulating data, hindering the ability to identify effective treatments or patient subgroups during the trial.

PhaseV offers a machine learning platform that leverages causal inference and multi-arm bandit algorithms to optimize clinical trial design and execution. The platform enables adaptive trial designs, allowing for real-time adjustments based on accumulating data. By detecting hidden signals and heterogeneous treatment effects, PhaseV helps clinical teams make data-driven decisions, optimize resource allocation, and increase the likelihood of identifying successful treatments and patient subpopulations. The platform's intuitive interface simplifies the implementation of advanced statistical methods, making adaptive trials more accessible to clinical teams.

Adaptive trial design simulation to evaluate the benefits of adaptive designs

Real-time optimization using multi-arm bandit algorithms for efficient exploration and exploitation of treatment options

Causal machine learning to detect hidden signals and heterogeneous treatment effects

Identification of subpopulations and endpoints likely to succeed in subsequent trials

Translation of complex machine learning insights into actionable recommendations

Flexible, closed-loop software architecture for real-time adaptations and integrations

Intuitive interface designed for clinical teams to simplify use and maximize efficacy

PhaseV primarily targets clinical teams, pharmaceutical companies, and research institutions involved in designing and executing clinical trials, particularly those seeking to improve trial efficiency and success rates.